IRIS - Res&Arch Institutional Research Information System - Research & Archive

Roila, Fausto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.171
AS - Asia 2.628
EU - Europa 2.086
SA - Sud America 632
Continente sconosciuto - Info sul continente non disponibili 180
AF - Africa 87
OC - Oceania 2
AN - Antartide 1
Totale 9.787
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.919
SG - Singapore 1.380
BR - Brasile 478
IT - Italia 471
IE - Irlanda 468
RU - Federazione Russa 367
HK - Hong Kong 358
CN - Cina 308
FR - Francia 245
VN - Vietnam 160
DE - Germania 119
CA - Canada 98
UA - Ucraina 77
GB - Regno Unito 73
IN - India 71
BD - Bangladesh 66
SE - Svezia 65
FI - Finlandia 52
AR - Argentina 48
MX - Messico 39
KR - Corea 37
TR - Turchia 36
IQ - Iraq 32
CO - Colombia 26
PK - Pakistan 26
AT - Austria 25
ES - Italia 24
EC - Ecuador 23
ZA - Sudafrica 23
NL - Olanda 22
ID - Indonesia 21
CR - Costa Rica 20
JP - Giappone 20
PL - Polonia 19
BE - Belgio 18
PH - Filippine 18
SA - Arabia Saudita 18
VE - Venezuela 15
JM - Giamaica 14
PR - Porto Rico 14
UZ - Uzbekistan 14
GT - Guatemala 13
CL - Cile 12
MA - Marocco 12
PY - Paraguay 11
TT - Trinidad e Tobago 11
HN - Honduras 10
IL - Israele 10
KE - Kenya 10
SV - El Salvador 10
EG - Egitto 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
BO - Bolivia 7
DZ - Algeria 7
JO - Giordania 7
NI - Nicaragua 7
DO - Repubblica Dominicana 6
GP - Guadalupe 6
SC - Seychelles 6
CH - Svizzera 5
LT - Lituania 5
TN - Tunisia 5
CW - ???statistics.table.value.countryCode.CW??? 4
EE - Estonia 4
KZ - Kazakistan 4
LB - Libano 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BG - Bulgaria 3
DK - Danimarca 3
ET - Etiopia 3
NP - Nepal 3
PS - Palestinian Territory 3
RO - Romania 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BY - Bielorussia 2
GE - Georgia 2
GH - Ghana 2
GR - Grecia 2
GY - Guiana 2
PT - Portogallo 2
SN - Senegal 2
SR - Suriname 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AQ - Antartide 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BZ - Belize 1
CG - Congo 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
EU - Europa 1
Totale 9.595
Salva come PNG Salva come JPEG
Città #
Singapore 946
San Jose 486
Dublin 468
Ashburn 398
Hong Kong 357
Chandler 347
Santa Clara 211
Council Bluffs 183
Moscow 163
Boardman 162
Princeton 136
Altamura 135
Medford 127
Lawrence 125
Lauterbourg 116
Los Angeles 112
The Dalles 99
New York 73
Ho Chi Minh City 61
Perugia 57
São Paulo 56
Beijing 53
North Bergen 41
Jacksonville 38
Dallas 37
Seoul 37
San Mateo 33
Piscataway 30
Munich 29
Rome 29
Hanoi 26
Helsinki 26
Milan 26
Redmond 26
Andover 25
Ann Arbor 25
Chicago 24
Nuremberg 23
Montreal 22
Frankfurt am Main 21
San Paolo di Civitate 20
Shanghai 20
Atlanta 19
Brooklyn 19
Bologna 18
Houston 18
San José 18
Warsaw 18
Naples 17
Rio de Janeiro 17
Tokyo 17
Brussels 16
Toronto 16
Wilmington 16
Lahore 15
Calgary 14
Chennai 14
Guayaquil 14
Mexico City 14
Charlotte 13
Phoenix 13
Baghdad 12
Buffalo 12
Columbus 12
Denver 12
Johannesburg 12
Orem 12
San Francisco 12
Stockholm 12
Brasília 11
Kingston 11
London 11
Napoli 11
Amsterdam 10
Boston 10
Dhaka 10
Falkenstein 10
Guangzhou 10
Istanbul 10
Tashkent 10
Turin 10
Turku 10
Mumbai 9
Ankara 8
Boydton 8
New Delhi 8
San Salvador 8
Belo Horizonte 7
Caracas 7
Des Moines 7
Haiphong 7
Huskvarna 7
Jeddah 7
Medellín 7
Norwalk 7
Philadelphia 7
Riyadh 7
San Juan 7
Seattle 7
Vienna 7
Totale 6.097
Salva come PNG Salva come JPEG
Nome #
Primitive thyroid lymphomas 138
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 135
Supportive care in cancer—a MASCC perspective 134
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 131
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 131
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 123
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 121
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 119
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 113
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 111
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 106
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 102
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 100
Surgical treatment of primitive thyroid lymphoma 100
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 100
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 100
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 99
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 99
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 98
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 98
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 97
Raccomandazioni cliniche per il melanoma cutaneo 95
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 91
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 91
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 90
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 90
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 90
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 89
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 89
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 89
Acute emesis: moderately emetogenic chemotherapy 89
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 87
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 87
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 87
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 87
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 87
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 87
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 86
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 85
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO) 84
A new payment-by-results method for determining the fair price of new oncological drugs 81
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 81
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 80
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 80
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 80
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 80
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 80
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 79
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 78
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 77
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 75
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 74
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 74
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 74
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE 73
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 73
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 72
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 71
State of the art of antiemetic therapy 71
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 71
New antiemetic drugs 70
Optimal Management of Fatigue 70
Targeted therapy for advanced cutaneous melanoma 68
Prevention and treatment of pandemic influenza in cancer patients. 68
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 68
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 68
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 68
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 67
Juvenile papillomatosis of the breast in young male: a case report 67
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group 67
DOACs in patients with brain cancers: promising but still a long way to go 66
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 66
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 66
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 64
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 63
Management of cancer pain: ESMO Clinical Practice Guidelines 63
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 63
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 63
Conflict of interest among Italian medical oncologists: A national survey 62
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 62
The cost of chemotherapy-induced nausea and vomiting in Italy 61
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 60
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 60
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 59
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 59
Cognitive impairment and chemotherapy: a brief overview 58
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 57
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management 56
Chemotherapy-induced nausea and vomiting 56
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting (Reprinted) 56
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 55
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study 55
Renal cancer 55
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 55
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges 54
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 54
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 54
Management of febrile neutropenia: ESMO Clinical Recommendations 54
Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) 53
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) 53
Totale 8.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.255
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022473 0 0 0 0 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20251.771 9 165 27 63 198 74 50 147 470 116 268 184
2025/20263.700 306 230 263 462 495 242 615 237 402 316 82 50
2026/20271.479 70 173 249 777 210 0 0 0 0 0 0 0
Totale 9.787